Inhibition of Type I Insulin-Like Growth Factor Receptor Signaling Attenuates the Development of Breast Cancer Brain Metastasis

• Sandra M. Saldana,

  Affiliations Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Cancer Biology Program, the University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America

  ⨯
• Heng-Huan Lee,

  Affiliations Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Cancer Biology Program, the University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America

  ⨯
• Frank J. Lowery,

  Affiliations Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Cancer Biology Program, the University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America

  ⨯
• Yekaterina B. Khotskaya,

  Affiliation Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Weiya Xia,

  Affiliation Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Chenyu Zhang,

  Affiliation Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Shih-Shin Chang,

  Affiliations Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Cancer Biology Program, the University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America

  ⨯
• Chao-Kai Chou,

  Affiliations Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Cancer Biology Program, the University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America, Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University, Taichung, Taiwan

  ⨯
• Patricia S. Steeg,

  Affiliation Women’s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America

  ⨯
• Dihua Yu,

  Affiliations Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Cancer Biology Program, the University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America

  ⨯
• Mien-Chie Hung

  * E-mail: mhung@mdanderson.org

  Affiliations Department of Molecular and Cellular Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, Cancer Biology Program, the University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, United States of America, Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University, Taichung, Taiwan, Department of Biotechnology, Asia University, Taichung, Taiwan

  ⨯